当前位置: 首页 >> 检索结果
9341. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.
作者: Inmaculada Hernandez.;Alvaro San-Juan-Rodriguez.;Chester B Good.;Walid F Gellad.
来源: JAMA. 2020年323卷9期854-862页
Most studies that have examined drug prices have focused on list prices, without accounting for manufacturer rebates and other discounts, which have substantially increased in the last decade.
9342. US Health Care Spending by Payer and Health Condition, 1996-2016.
作者: Joseph L Dieleman.;Jackie Cao.;Abby Chapin.;Carina Chen.;Zhiyin Li.;Angela Liu.;Cody Horst.;Alexander Kaldjian.;Taylor Matyasz.;Kirstin Woody Scott.;Anthony L Bui.;Madeline Campbell.;Herbert C Duber.;Abe C Dunn.;Abraham D Flaxman.;Christina Fitzmaurice.;Mohsen Naghavi.;Nafis Sadat.;Peter Shieh.;Ellen Squires.;Kai Yeung.;Christopher J L Murray.
来源: JAMA. 2020年323卷9期863-884页
US health care spending has continued to increase and now accounts for 18% of the US economy, although little is known about how spending on each health condition varies by payer, and how these amounts have changed over time.
9343. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
作者: Fred D Ledley.;Sarah Shonka McCoy.;Gregory Vaughan.;Ekaterina Galkina Cleary.
来源: JAMA. 2020年323卷9期834-843页
Understanding the profitability of pharmaceutical companies is essential to formulating evidence-based policies to reduce drug costs while maintaining the industry's ability to innovate and provide essential medicines.
9352. Sponsorship and Funding for Gene Therapy Trials in the United States.
作者: Zachary Kassir.;Ameet Sarpatwari.;Brian Kocak.;Courtney C Kuza.;Walid F Gellad.
来源: JAMA. 2020年323卷9期890-891页
This study characterizes government, academia, and private funding for gene therapy trials in the United States by technology type and therapeutic and disease area.
|